FOXM1 and ovarian carcinoma: Indeed, the potential of existing FOXM1 inhibitors as a therapeutic against ovarian cancer has been actively explored both in vitro and in vivo and, at the same time, the development of novel inhibitors of FOXM1 intended particularly for use in the treatment of ovarian cancer is enthusiastically pursued, with some being reported just recently [5,6,7].